Pratik Shah, Ph.D.

Pratik joined Thomas, McNerney & Partners in 2004 and represents Thomas, McNerney & Partners on the boards of Cebix Incorporated, and SGB, Inc. He was also a board member at CNS Therapeutics, Inc. prior to its acquisition in 2012, and Ocera Therapeutics, Inc. (OCRX).  Prior to joining the firm, he was the Chief Business Officer and co-founder of Kalypsys, Inc., a biopharmaceutical company focused on the discovery and clinical development of new medicines for cancer, inflammation and metabolic disease using its proprietary automation technologies. Before co-founding Kalypsys, Pratik was at McKinsey & Company, where he focused on biotechnology and venture capital projects. He was formerly a co-founder and VP of Operations at NephRx Corporation, a start-up company focused on the discovery of therapeutic proteins for renal disease. Pratik holds a B.S. in Biological Sciences from the University of California at Irvine and both a Ph.D. in Biochemistry & Molecular Biology and an M.B.A. from the University of Chicago.